Senior Advisor Subject Matter Expert (SME) with Patient Advocacy Expertise for the NINDS Ultra-rare Gene-based Therapy (URGenT) Network

COMBINED SYNOPSIS / SOLICITATION (COMPETITIVE) Title: Senior Advisor Subject Matter Expert (SME) with Patient Advocacy Expertise for the NINDS Ultra-rare Gene-based Therapy (URGenT) Network (i) This is a combined synopsis/solicitation for commercial products or commercial services prepared in accordance with RFO Part 12. This announcement constitutes the only solicitation. Offers are being requested and a separate written solicitation will not be issued. The solicitation number is 7571PS27Q00015 issued as a Request for Quote for a Senior Advisor to act as a Subject Matter Expert (SME) with Patient Advocacy Expertise The Government reserves the right to make one award, multiple awards, or no awards as a result of this solicitation. This acquisition is set-aside for small business concerns. This solicitation incorporates provisions and clauses by reference. The full text of provisions and clauses may be accessed electronically at www.acquisition.gov . The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. (ii) This requirement is for the following services: NINDS is seeking to procure a highly experienced executive-level , drug discovery and development Senior Advisor 2 Subject Matter Expert (SME) with experience in the area of Patient Advocacy to provide feedback to the NINDS program leadership and technical guidance on drug discovery and development projects within the URGenT portfolio. The Contractor will serve as a member of the URGenT External Counselor Board (ECB), which provides strategic guidance on URGenT projects and on occasion other NINDS drug discovery and development programs. (iii) Description of requirement: The NIH is seeking to procure a highly experienced executive-level Senior Advisor 2 , drug discovery and development subject matter expert with experience in the area Patient Advocacy to provide feedback to the NIH program leadership and technical guidance on drug discovery and development projects as members o